Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
At the 2020 ASH Annual Meeting, new clinical trial data in nonmalignant hematologic disorders were reported, including novel approaches in immune thrombocytopenia (ITP), hereditary blood disorders (hemophilia, sickle cell disease, and β-thalassemia), and therapies for acute or chronic graft-vs-host disease (GVHD). In this module, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, review and discuss the clinical implications of key studies in these hematologic disorders that were presented at the meeting.
Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that can also be found here, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.
Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.